Xigris (Zy-gris, drotrecogin alfa), a new biotech drug for treating severe sepsis
January 2002
Lilly is now marketing Xigris (Zy-gris, drotrecogin alfa), a new biotech drug for treating severe sepsis.
Until now the main treatment for severe sepsis was antibiotics.
Xigris is the first drug shown to improve survival in cases of severe septic infections. It reduces deaths by about 6%...or saves one life for every 16 patients who are treated.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote